Altamira Therapeutics LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% in Altamira Therapeutics Ltd., holding 473,870 common shares.
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Altamira Therapeutics Ltd., holding 478,547 common shares as of December 31, 2024.